

TAILORED-CHIP

Tailored Antiplatelet Therapy in High-Risk Patients Undergoing Complex PCI

PURPOSE: To evaluate the safety and efficacy of tailored antithrombotic therapy with early intensified (ticagrelor + aspirin) and late de-escalated (clopidogrel only) strategy, compared to standard dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI)

STUDY DESIGN: Prospective, multicenter, randomized, open-label, non-inferiority phase 4 trial; N=2018

KEY TAKEAWAYS: Standard DAPT remains the appropriate therapy over tailored therapy for patients after complex PCI.

	Tailored Antiplatelet Therapy (%)	Conventional DAPT (%)	HR (95% CI)	P value
Primary outcome				
Composite of death from any cause, myocardial infarction, stroke, stent thrombosis, urgent revascularization, or clinically relevant bleeding at 1 year	669 (10.5)	747 (8.8)	1.19 (0.90-1.58)	0.21
RESULTS: Tailored therapy demonstrated no significant difference in major ischemic events, but significantly higher incidence of clinically relevant bleeding, compared to standard DAPT following complex PCI.				